TRK Inhibitors in Lung and GI Cancers

EP. 1: Role of NTRK Inhibitors

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 2: Variants of NTRK Fusions in Solid Tumors

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 3: Evolution of NGS Testing in Lung Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 4: Using Molecular Testing in GI Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 5: Approaching Genomic Testing for NTRK Fusions

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 6: Genomic Testing for NTRK Fusions in Lung and GI Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 7: Driver Mutations in NTRK Fusion-Positive Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 8: Advice for Interpreting NGS Reports

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 9: Early Development of TRK Inhibitors

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 10: Efficacy of TRK Inhibitors

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 11: TRK Inhibitor in GI Cancers: Adverse Effect Profile

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 12: Approaching Treatment for TRK Fusion–Positive Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 13: Acquired Resistance in TRK Fusion-Positive Cancers

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 14: Challenges for TRK Fusion–Targeting Agents

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 15: Future of NTRK Fusions

ByJohn L. Marshall, MD, MedStar Georgetown University Hospital,Tanios S. Bekaii-Saab, MD, Mayo Clinic,Shubham Pant, MD, MD Anderson Cancer Center,Jyoti D. Patel, MD, Robert H. Lurie Comprehensive Cancer Center,Luis E. Raez, MD, Memorial Healthcare System,Mark A. Socinski, MD, AdventHealth Cancer Institute

May 21st 2020

EP. 1: Role of NTRK Inhibitors

EP. 2: Variants of NTRK Fusions in Solid Tumors

EP. 3: Evolution of NGS Testing in Lung Cancers

EP. 4: Using Molecular Testing in GI Cancers

EP. 5: Approaching Genomic Testing for NTRK Fusions

EP. 6: Genomic Testing for NTRK Fusions in Lung and GI Cancers

EP. 7: Driver Mutations in NTRK Fusion-Positive Cancers

EP. 8: Advice for Interpreting NGS Reports

EP. 9: Early Development of TRK Inhibitors

EP. 10: Efficacy of TRK Inhibitors

EP. 11: TRK Inhibitor in GI Cancers: Adverse Effect Profile

EP. 12: Approaching Treatment for TRK Fusion–Positive Cancers

EP. 13: Acquired Resistance in TRK Fusion-Positive Cancers

EP. 14: Challenges for TRK Fusion–Targeting Agents

EP. 15: Future of NTRK Fusions

Trending on OncLive

FDA Grants Fast Track Designation to Pelareorep in Pretreated SCAC

PRAME-Directed Therapies Advance Melanoma Treatment Across Clinical Settings

META 10-19 Elicits High Complete Response Rate at Ultra-Low Doses in High-Risk R/R DLBCL

Sonrotoclax and Next-Generation BCL-2 Inhibitors for Treating CLL

Dr Falchi on Critical Unmet Needs and Important Next Steps in DLBCL